AU2019251518A1 - Method of monitoring response to a treatment - Google Patents

Method of monitoring response to a treatment Download PDF

Info

Publication number
AU2019251518A1
AU2019251518A1 AU2019251518A AU2019251518A AU2019251518A1 AU 2019251518 A1 AU2019251518 A1 AU 2019251518A1 AU 2019251518 A AU2019251518 A AU 2019251518A AU 2019251518 A AU2019251518 A AU 2019251518A AU 2019251518 A1 AU2019251518 A1 AU 2019251518A1
Authority
AU
Australia
Prior art keywords
fold
subject
wnt
cancer
mmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019251518A
Other languages
English (en)
Inventor
Kristen GEORGIOU
Tina Lavranos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018901242A external-priority patent/AU2018901242A0/en
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Publication of AU2019251518A1 publication Critical patent/AU2019251518A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019251518A 2018-04-13 2019-04-12 Method of monitoring response to a treatment Abandoned AU2019251518A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018901242 2018-04-13
AU2018901242A AU2018901242A0 (en) 2018-04-13 Method of monitoring response to a treatment
PCT/AU2019/050334 WO2019195897A1 (en) 2018-04-13 2019-04-12 Method of monitoring response to a treatment

Publications (1)

Publication Number Publication Date
AU2019251518A1 true AU2019251518A1 (en) 2020-09-24

Family

ID=68163410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019251518A Abandoned AU2019251518A1 (en) 2018-04-13 2019-04-12 Method of monitoring response to a treatment

Country Status (5)

Country Link
US (1) US20210148894A1 (cg-RX-API-DMAC7.html)
JP (1) JP7292306B2 (cg-RX-API-DMAC7.html)
CN (1) CN111971559A (cg-RX-API-DMAC7.html)
AU (1) AU2019251518A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019195897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944649C (en) * 2014-04-04 2022-06-21 Bionomics, Inc. Humanized antibodies that bind lgr5

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1171771B1 (en) 1999-04-09 2005-06-29 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker
CN101166979A (zh) * 2005-05-11 2008-04-23 霍夫曼-拉罗奇有限公司 化学治疗应答者的确定
US20080305962A1 (en) * 2005-07-29 2008-12-11 Ralph Markus Wirtz Methods and Kits for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapies
WO2012129517A2 (en) * 2011-03-24 2012-09-27 Dyax Corp. Evaluating protein expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
TWI504390B (zh) * 2012-09-18 2015-10-21 Univ China Medical 苯醌類化合物應用於抑制黑色素瘤細胞之Ｗｎｔ／β－ｃａｔｅｎｉｎ訊息途徑之用途
RU2702908C2 (ru) * 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы

Also Published As

Publication number Publication date
EP3775913A1 (en) 2021-02-17
US20210148894A1 (en) 2021-05-20
JP2021521437A (ja) 2021-08-26
JP7292306B2 (ja) 2023-06-16
WO2019195897A1 (en) 2019-10-17
CN111971559A (zh) 2020-11-20

Similar Documents

Publication Publication Date Title
JP6430560B2 (ja) 前立腺癌マーカーとしてのホスホジエステラーゼ４ｄ７
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
JP2020528268A (ja) 免疫チェックポイント遮断療法に対するレスポンダー及び非レスポンダーを特定するためのシステム及び方法
RU2013113439A (ru) Идентификация опухолеассоциированных антигенов для диагностики и терапии
EP3359688B1 (en) Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
JP7630906B2 (ja) 利尿薬耐性の治療
EP3617231A1 (en) Anti-gpc-1 antibody
US10330682B2 (en) Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using same
JP6909795B2 (ja) 胃癌の検出および治療のための組成物および方法
JP5918694B2 (ja) 前立腺がんのマーカーとしてのホスホジエステラーゼ９ａ
US20210148894A1 (en) Method of monitoring response to a treatment
US9084775B2 (en) Methods for diagnosing and treating neuroendocrine cancer
US7842468B2 (en) Methods for diagnosing and treating neuroendocrine cancer
JP2021522478A (ja) 選択された患者の心血管疾患を治療するための組成物および方法
US9410955B2 (en) Method for predicting the risk of developing a colonic neoplasia
Gao et al. SZ168 alleviates bleomycin-induced pulmonary fibrosis by inhibiting podoplanin-induced platelet activation
US9694072B2 (en) Methods for diagnosing and treating neuroendocrine cancer
CN105331686B (zh) Myosin9b蛋白特异性抗体的制备及Myosin9b基因家族变化在肿瘤诊断及预后中的应用
WO2025044942A1 (en) Use of secreted cdcp1 for improved treatment of non-alcoholic steatohepatitis
US8415109B2 (en) Methods for diagnosing and treating neuroendocrine cancer
US20240280590A1 (en) Compositions and methods for facioscapulohumeral muscular dystrophy biomarker detection
JP6964322B2 (ja) ループス腎炎を処置または予防するための医薬組成物およびループス腎炎のバイオマーカー
US20080145849A1 (en) Methods for diagnosing and treating neuroendocrine cancer
CN116940844A (zh) 新颖生物标志物及其用途
AU2014208271A1 (en) Tumor tissue based biomarkers for bevacizumab combination therapies

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application